Cargando…

Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study

This study aimed to evaluate the antibody and cellular responses to different coronavirus 2019 (COVID-19) vaccination regimens in patients with cirrhosis and to assess the antibody response after a vaccine booster. We conducted a prospective observational study of 89 patients with cirrhosis and 41 h...

Descripción completa

Detalles Bibliográficos
Autores principales: Sripongpun, Pimsiri, Pinpathomrat, Nawamin, Sophonmanee, Ratchanon, Ongarj, Jomkwan, Seepathomnarong, Purilap, Seeyankem, Bunya, Chamroonkul, Naichaya, Piratvisuth, Teerha, Kaewdech, Apichat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534824/
https://www.ncbi.nlm.nih.gov/pubmed/37766131
http://dx.doi.org/10.3390/vaccines11091455
_version_ 1785112485146132480
author Sripongpun, Pimsiri
Pinpathomrat, Nawamin
Sophonmanee, Ratchanon
Ongarj, Jomkwan
Seepathomnarong, Purilap
Seeyankem, Bunya
Chamroonkul, Naichaya
Piratvisuth, Teerha
Kaewdech, Apichat
author_facet Sripongpun, Pimsiri
Pinpathomrat, Nawamin
Sophonmanee, Ratchanon
Ongarj, Jomkwan
Seepathomnarong, Purilap
Seeyankem, Bunya
Chamroonkul, Naichaya
Piratvisuth, Teerha
Kaewdech, Apichat
author_sort Sripongpun, Pimsiri
collection PubMed
description This study aimed to evaluate the antibody and cellular responses to different coronavirus 2019 (COVID-19) vaccination regimens in patients with cirrhosis and to assess the antibody response after a vaccine booster. We conducted a prospective observational study of 89 patients with cirrhosis and 41 healthy volunteers who received two COVID-19 vaccine doses. Next, we prospectively evaluated 24 patients with cirrhosis who received a booster COVID-19 vaccine dose. In both studies, blood samples were collected before and 4 weeks after vaccination, and anti-spike receptor-binding domain protein IgG levels, T-cell phenotypes, and effector functions were assessed. The heterologous vaccine regimen (CoronaVac [SV]/AstraZeneca [AZ]) produced a better antibody response and CD4+IFNg+ T cell response compared to homogeneous vaccine regimens. The antibody response after the second dose of the vaccine was similar in patients with cirrhosis and healthy volunteers. Patients who received a booster dose of the mRNA vaccine had significantly increased antibody titers compared to those who received the AZ vaccine. In patients with cirrhosis, heterologous vaccination with SV/AZ resulted in a better immune response than the AZ/AZ and SV/SV regimens. Moreover, a booster dose of the mRNA vaccine led to a greater increase in antibody titers compared to the AZ vaccine.
format Online
Article
Text
id pubmed-10534824
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105348242023-09-29 Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study Sripongpun, Pimsiri Pinpathomrat, Nawamin Sophonmanee, Ratchanon Ongarj, Jomkwan Seepathomnarong, Purilap Seeyankem, Bunya Chamroonkul, Naichaya Piratvisuth, Teerha Kaewdech, Apichat Vaccines (Basel) Article This study aimed to evaluate the antibody and cellular responses to different coronavirus 2019 (COVID-19) vaccination regimens in patients with cirrhosis and to assess the antibody response after a vaccine booster. We conducted a prospective observational study of 89 patients with cirrhosis and 41 healthy volunteers who received two COVID-19 vaccine doses. Next, we prospectively evaluated 24 patients with cirrhosis who received a booster COVID-19 vaccine dose. In both studies, blood samples were collected before and 4 weeks after vaccination, and anti-spike receptor-binding domain protein IgG levels, T-cell phenotypes, and effector functions were assessed. The heterologous vaccine regimen (CoronaVac [SV]/AstraZeneca [AZ]) produced a better antibody response and CD4+IFNg+ T cell response compared to homogeneous vaccine regimens. The antibody response after the second dose of the vaccine was similar in patients with cirrhosis and healthy volunteers. Patients who received a booster dose of the mRNA vaccine had significantly increased antibody titers compared to those who received the AZ vaccine. In patients with cirrhosis, heterologous vaccination with SV/AZ resulted in a better immune response than the AZ/AZ and SV/SV regimens. Moreover, a booster dose of the mRNA vaccine led to a greater increase in antibody titers compared to the AZ vaccine. MDPI 2023-09-04 /pmc/articles/PMC10534824/ /pubmed/37766131 http://dx.doi.org/10.3390/vaccines11091455 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sripongpun, Pimsiri
Pinpathomrat, Nawamin
Sophonmanee, Ratchanon
Ongarj, Jomkwan
Seepathomnarong, Purilap
Seeyankem, Bunya
Chamroonkul, Naichaya
Piratvisuth, Teerha
Kaewdech, Apichat
Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study
title Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study
title_full Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study
title_fullStr Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study
title_full_unstemmed Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study
title_short Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study
title_sort heterologous covid-19 vaccination and booster with mrna vaccine provide enhanced immune response in patients with cirrhosis: a prospective observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534824/
https://www.ncbi.nlm.nih.gov/pubmed/37766131
http://dx.doi.org/10.3390/vaccines11091455
work_keys_str_mv AT sripongpunpimsiri heterologouscovid19vaccinationandboosterwithmrnavaccineprovideenhancedimmuneresponseinpatientswithcirrhosisaprospectiveobservationalstudy
AT pinpathomratnawamin heterologouscovid19vaccinationandboosterwithmrnavaccineprovideenhancedimmuneresponseinpatientswithcirrhosisaprospectiveobservationalstudy
AT sophonmaneeratchanon heterologouscovid19vaccinationandboosterwithmrnavaccineprovideenhancedimmuneresponseinpatientswithcirrhosisaprospectiveobservationalstudy
AT ongarjjomkwan heterologouscovid19vaccinationandboosterwithmrnavaccineprovideenhancedimmuneresponseinpatientswithcirrhosisaprospectiveobservationalstudy
AT seepathomnarongpurilap heterologouscovid19vaccinationandboosterwithmrnavaccineprovideenhancedimmuneresponseinpatientswithcirrhosisaprospectiveobservationalstudy
AT seeyankembunya heterologouscovid19vaccinationandboosterwithmrnavaccineprovideenhancedimmuneresponseinpatientswithcirrhosisaprospectiveobservationalstudy
AT chamroonkulnaichaya heterologouscovid19vaccinationandboosterwithmrnavaccineprovideenhancedimmuneresponseinpatientswithcirrhosisaprospectiveobservationalstudy
AT piratvisuthteerha heterologouscovid19vaccinationandboosterwithmrnavaccineprovideenhancedimmuneresponseinpatientswithcirrhosisaprospectiveobservationalstudy
AT kaewdechapichat heterologouscovid19vaccinationandboosterwithmrnavaccineprovideenhancedimmuneresponseinpatientswithcirrhosisaprospectiveobservationalstudy